典型文献
Pathophysiology and therapeutic advances in myeloma bone disease
文献摘要：
Bone disease is the most common complication in patients with multiple myeloma (MM), and it may lead to skeletal-related events (SREs) such as bone pain, pathological fractures, and spinal cord compression, which impair a patients' quality of life and survival. The pathogenesis of myeloma bone disease (MBD) involves disruption of bone reconstitution balance including excessive activation of osteoclasts, inhibition of osteoblasts, and participation of osteocytes and bone marrow stromal cells. Various factors, such as the receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG), dickkopf-1 (DKK-1), sclerostin, and activin-A, are involved in the development of MBD. Bisphosphonates and the anti-RANKL antibody denosumab are currently the main treatment options for MBD, delaying the onset of SREs. Denosumab is preferred in patients with MM and renal dysfunction. Although effective drugs have been approved, antimyeloma therapy is the most important method for controlling bone disease.
文献关键词：
bone disease;multiple myeloma;therapies
中图分类号：
作者姓名：
Zhang Fujing;Zhuang Junling
作者机构：
Department of Hematology, Peking Union Medical College Hospital, Beijing, China;Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
文献出处：
引用格式：
[1]Zhang Fujing;Zhuang Junling-.Pathophysiology and therapeutic advances in myeloma bone disease)[J].慢性疾病与转化医学（英文）,2022(04):264-270
A类：
Pathophysiology,dickkopf,Bisphosphonates,denosumab,antimyeloma
B类：
therapeutic,advances,bone,disease,Bone,most,common,complication,patients,multiple,MM,may,lead,skeletal,related,events,SREs,such,pain,pathological,fractures,spinal,cord,compression,which,impair,quality,life,survival,pathogenesis,MBD,involves,disruption,reconstitution,balance,including,excessive,activation,osteoclasts,inhibition,osteoblasts,participation,osteocytes,marrow,stromal,cells,Various,factors,receptor,activator,nuclear,ligand,RANKL,osteoprotegerin,OPG,DKK,sclerostin,activin,are,involved,development,antibody,currently,main,treatment,options,delaying,onset,Denosumab,preferred,renal,dysfunction,Although,effective,drugs,have,been,approved,therapy,important,method,controlling,therapies
AB值：
0.616135
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
